The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Visage Imaging, a subsidiary of Pro Medicus (PME), signs a $32 million, eight-year contract with Inova Health System
  • The contract will see Pro Medicus’ Image Visage 7 Enterprise Imaging Platform implemented throughout Inova and Fairfax Radiology
  • Visage 7 delivers quick, multi-dimensional images that are streamed through an intelligent thin-client viewer
  • Planning for the rollout of Visage 7 is expected to begin immediately with initial go-lives scheduled for the second half of the year
  • Pro Medicus was up 2.12 per cent with shares trading at $48.20

Visage Imaging, a subsidiary of Pro Medicus (PME), has signed a $32 million, eight-year contract with Inova Health System.

The contract will see Pro Medicus’ Image Visage 7 Enterprise Imaging Platform implemented throughout Inova and Fairfax Radiology.

Visage 7 delivers quick, multi-dimensional images that are streamed through an intelligent thin-client viewer (essentially a web-based document viewing and collaboration tool).

Planning for the rollout of Visage 7 is expected to begin immediately with initial go-lives scheduled for the second half of the year.

“This is our fourth major contract in the IDN space in less than 18 months which further underpins the strong momentum we continue to build not only in this segment of the market but also the North American market as a whole,” CEO Dr Sam Hupert said.

“Our pipeline remains strong. Deals like this confirm our view that Visage 7, with its proven cloudnative technology provides us with a significant strategic advantage that addresses these opportunities across a growing segment of the market both in North America and other regions.”

Pro Medicus was up 2.12 per cent with shares trading at $48.20 at 3:24 pm AEST.

PME by the numbers
More From The Market Online
Stem cell concept

Mesoblast dips on ‘belief’ it’s not subject to US tariffs – despite Singaporean lab

Mesoblast (ASX:MSB) has seen shares fall just shy of -3% heading into lunchtime trades despite apparent…
Children's hospital concept

Mesoblast kicks off treatment for first 3 kids with graft-host disease. So why are shares down?

otCopper favourite Mesoblast (ASX:MSB) has announced it's begun treating the first 3 children with skin graft-versus-host…
CSL Limited logo

CSL survives a brutal sell-off but dips on US tariff response as investors eye pharma risk

CSL Ltd (ASX:CSL) has seen shares fall nearly half a percent in afternoon trades on Thursday…
Fisher & Paykel

Fisher & Paykel shrugs off red Thursday as investors satisfied tariff risks under control

Perhaps surprisingly, FIsher & Paykel Healthcare (ASX:FPH) – a company that produces around 40% of its…